

### References

- Araujo, J. P., Azevedo, A., Lourenco, P., Rocha-Goncalves, F., Ferreira, A., & Bettencourt, P. (2006). Intraindividual variation of amino-terminal pro-B-type natriuretic peptide levels in patients with stable heart failure. *American Journal of Cardiology*, 98(9), 1248-1250. doi:10.1016/j.amjcard.2006.06.017
- Balion, C. M., Santaguida, P., McKelvie, R., Hill, S. A., McQueen, M. J., Worster, A., & Raina, P. S. (2008). Physiological, pathological, pharmacological, biochemical and hematological factors affecting BNP and NT-proBNP. *Clinical Biochemistry*, 41(4-5), 231-239. doi:10.1016/j.clinbiochem.2007.10.005
- Bettencourt, P., Azevedo, A., Pimenta, J., Frioies, F., Ferreira, S., & Ferreira, A. (2004). N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. *Circulation*, 110(15), 2168-2174. doi:10.1161/01.CIR.0000144310.04433.BE
- Bruins, S., Fokkema, M. R., Romer, J. W., Dejongste, M. J., van der Dijs, F. P., van den Ouweland, J. M., & Muskiet, F. A. (2004). High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. *Clinical Chemistry*, 50(11), 2052-2058. doi:10.1373/clinchem.2004.038752
- Carpenter, J., & Bithell, J. (2000). Bootstrap confidence intervals: When, which, what? A practical guide for medical statisticians. *Statistics in Medicine*, 19(9), 1141-1164.
- Chen, Y. J., Sung, S. H., Cheng, H. M., Huang, W. M., Wu, C. L., Huang, C. J., . . . Chen, C. H. (2017). Performance of AHEAD Score in an Asian cohort of acute heart failure with either preserved or reduced left ventricular systolic function. *Journal American Heart Association*, 6(5). doi:10.1161/JAHA.116.004297
- Eurlings, L. W., van Pol, P. E., Kok, W. E., van Wijk, S., Lodewijks-van der Bolt, C., Balk, A.

- H., . . . Pinto, Y. M. (2010). Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: Results of the PRIMA (Can PRO-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. *Journal of the American College of Cardiology*, 56(25), 2090-2100. doi:10.1016/j.jacc.2010.07.030
- Felker, G. M., Anstrom, K. J., Adams, K. F., Ezekowitz, J. A., Fiuzat, M., Houston-Miller, N., . . . O'Connor, C. M. (2017). Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: A Randomized clinical trial. *Journal American Medical Association*, 318(8), 713-720. doi:10.1001/jama.2017.10565
- Frankenstein, L., Remppis, A., Frankenstein, J., Hess, G., Zdunek, D., Slottje, K., . . . Zugck, C. (2009). Variability of N-terminal probrain natriuretic peptide in stable chronic heart failure and its relation to changes in clinical variables. *Clinical Chemistry*, 55(5), 923-929. doi:10.1373/clinchem.2008.112052
- Glasziou, P. P., Irwig, L., Heritier, S., Simes, R. J., Tonkin, A., & Investigators, L. S. (2008). Monitoring cholesterol levels: Measurement error or true change? *Annals of Internal Medicine*, 148(9), 656-661.
- Hartmann, F., Packer, M., Coats, A. J., Fowler, M. B., Krum, H., Mohacsi, P., . . . Katus, H. A. (2004). Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: A substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. *Circulation*, 110(13), 1780-1786. doi:10.1161/01.CIR.0000143059.68996.A7
- Heidenreich, P. A., Albert, N. M., Allen, L. A., Bluemke, D. A., Butler, J., Fonarow, G. C., . . . Stroke, C. (2013). Forecasting the impact of heart failure in the United States: A policy statement from the American Heart Association. *Circulation: Heart Failure*,

6(3), 606-619. doi:10.1161/HHF.0b013e318291329a

Ho, K. K., Anderson, K. M., Kannel, W. B., Grossman, W., & Levy, D. (1993). Survival after the onset of congestive heart failure in Framingham Heart Study subjects. *Circulation*, 88(1), 107-115.

Januzzi, J. L., Jr., Rehman, S. U., Mohammed, A. A., Bhardwaj, A., Barajas, L., Barajas, J., . . . Semigran, M. J. (2011). Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. *Journal of the American College of Cardiology*, 58(18), 1881-1889. doi:10.1016/j.jacc.2011.03.072

Kang, S. H., Park, J. J., Choi, D. J., Yoon, C. H., Oh, I. Y., Kang, S. M., . . . Kor, H. F. R. (2015). Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF. *Heart*, 101(23), 1881-1888. doi:10.1136/heartjnl-2015-307782

Klersy, C., d'Eril, G. V., Barassi, A., Palladini, G., Comelli, M., Moratti, R., . . . Merlini, G. (2012). Advantages of the lognormal approach to determining reference change values for N-terminal propeptide B-type natriuretic peptide. *Clinica Chimica Acta*, 413(5-6), 544-547. doi:10.1016/j.cca.2011.11.012

Krauser, D. G., Lloyd-Jones, D. M., Chae, C. U., Cameron, R., Anwaruddin, S., Baggish, A. L., . . . Januzzi, J. L., Jr. (2005). Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: A ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. *American Heart Journal*, 149(4), 744-750. doi:10.1016/j.ahj.2004.07.010

Legaz-Arrese, A., Carranza-Garcia, L. E., Navarro-Orocio, R., Valadez-Lira, A., Mayolas-Pi, C., Munguia-Izquierdo, D., . . . George, K. (2017). Cardiac biomarker release after endurance exercise in male and female adults and adolescents. *Journal of Pediatrics*, 191, 96-102. doi:10.1016/j.jpeds.2017.08.061

Ministry of Health Labour and Welfare. (2015). Patient Survey 2015.

<https://www.mhlw.go.jp/toukei/saikin/hw/kanja/14/>

Ministry of Health Labour and Welfare. (2016). Vital Statistics 2016.

<https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei16/index.html>

Nishii, M., Inomata, T., Takehana, H., Naruke, T., Yanagisawa, T., Moriguchi, M., . . . Izumi,

T. (2008). Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomyopathy after decompensated heart failure.

*Journal of the American College of Cardiology*, 51(24), 2329-2335.

doi:10.1016/j.jacc.2007.11.085

Ohde, S., Deshpande, G. A., Yokomichi, H., Takahashi, O., Fukui, T., & Yamagata, Z. (2018).

HbA1c monitoring interval in patients on treatment for stable type 2 diabetes. A ten-year retrospective, open cohort study. *Diabetes Research & Clinical Practice*, 135,

166-171. doi:10.1016/j.diabres.2017.11.013

Ohde, S., McFadden, E., Deshpande, G. A., Yokomichi, H., Takahashi, O., Fukui, T., . . .

Yamagata, Z. (2016). Diabetes screening intervals based on risk stratification. *BMC Endocrine Disorders*, 16(1), 65. doi:10.1186/s12902-016-0139-1

Oke, J. L., Stevens, R. J., Gaitskell, K., & Farmer, A. J. (2012). Establishing an evidence base

for frequency of monitoring glycated haemoglobin levels in patients with Type 2

diabetes: Projections of effectiveness from a regression model. *Diabetic Medicine*,

29(2), 266-271. doi:10.1111/j.1464-5491.2011.03412.x

Ordonez-Llanos, J., Collinson, P. O., & Christenson, R. H. (2008). Amino-terminal pro-B-

type natriuretic peptide: Analytic considerations. *American Journal of Cardiology*,

101(3A), 9-15. doi:10.1016/j.amjcard.2007.11.013

Packer, M., McMurray, J. J., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., . . .

Coordinators. (2015). Angiotensin receptor neprilysin inhibition compared with

- enalapril on the risk of clinical progression in surviving patients with heart failure. *Circulation*, 131(1), 54-61. doi:10.1161/CIRCULATIONAHA.114.013748
- Perera, R., McFadden, E., McLellan, J., Lung, T., Clarke, P., Perez, T., . . . Stevens, R. (2015). Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: A systematic review with statistical and cost-effectiveness modelling. *Health Technology Assessment*, 19(100), 1-401, vii-viii. doi:10.3310/hta191000
- Pfisterer, M., Buser, P., Rickli, H., Gutmann, M., Erne, P., Rickenbacher, P., . . . Investigators, T.- C. (2009). BNP-guided vs symptom-guided heart failure therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. *Journal American Medical Association*, 301(4), 383-392. doi:10.1001/jama.2009.2
- Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., . . . Group, E. S. C. S. D. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *European Heart Journal*, 37(27), 2129-2200. doi:10.1093/eurheartj/ehw128
- R Core Team. (2018). R: *A language and environment for statistical computing*. Vienna, Austria <https://www.R-project.org/>
- Raymond, I., Groenning, B. A., Hildebrandt, P. R., Nilsson, J. C., Baumann, M., Trawinski, J., & Pedersen, F. (2003). The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. *Heart*, 89(7), 745-751.
- Schou, M., Gustafsson, F., Kjaer, A., & Hildebrandt, P. R. (2007). Long-term clinical variation of NT-proBNP in stable chronic heart failure patients. *European Heart*

*Journal*, 28(2), 177-182. doi:10.1093/eurheartj/ehl449

Spinar, J., Jarkovsky, J., Spinarova, L., Mebazaa, A., Gayat, E., Vitovec, J., . . . Parenica, J. (2016). AHEAD score--Long-term risk classification in acute heart failure.

*International Journal of Cardiology*, 202, 21-26. doi:10.1016/j.ijcard.2015.08.187

Stienen, S., Salah, K., Moons, A. H., Bakx, A. L., van Pol, P., Kortz, R. A. M., . . . Kok, W. E. (2018). NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-guided therapy in acute decompensated heart failure: PRIMA II randomized controlled trial (Can NT-ProBNP-guided therapy during hospital admission for acute decompensated heart failure reduce mortality and readmissions?). *Circulation*, 137(16), 1671-1683. doi:10.1161/CIRCULATIONAHA.117.029882

Wu, A. H., Smith, A., Wieczorek, S., Mather, J. F., Duncan, B., White, C. M., . . . Heller, G. (2003). Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. *American Journal of Cardiology*, 92(5), 628-631.

Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Jr., Colvin, M. M., . . . Westlake, C. (2017). 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *Journal of the American College of Cardiology*, 70(6), 776-803. doi:10.1016/j.jacc.2017.04.025

**Table 1. Equations for the applied random-effects model**

Equations or components	Interpretation
$Y_{it} = \beta_i \times t + \alpha_i + \varepsilon_{it}$	Random-effects model predicting the observed value.